SCHEMBL4486927

SCHEMBL4486927

CCOC(=O)c1c(-c2ccc(-c3sccc3SC)cc2)c(C#N)cn1C

nearest known ligand 0.41

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 6/20 0.41
ALDH1A1 P00352 6/20 0.38
HPGD P15428 3/20 0.38
L3MBTL1 Q9Y468 4/20 0.36
TDP1 Q9NUW8 2/20 0.36
GAA P10253 1/20 0.36
FNTA P49354 4/20 0.36
FNTB P49356 4/20 0.36
MEN1 O00255 3/20 0.35
KMT2A Q03164 3/20 0.35
GRIA2 P42262 1/20 0.35
GRIA4 P48058 1/20 0.35
MAPT P10636 4/20 0.33
POLB P06746 1/20 0.33
LMNA P02545 1/20 0.33
TSHR P16473 1/20 0.33
SMN1; SMN2 Q16637 1/20 0.33
IDO1 P14902 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8289279 0.91 KDM4E (0.44) KDM4EALDH1A1HPGDL3MBTL1TDP1
SCHEMBL8289572 0.86 GRIA4 (0.41) KDM4EALDH1A1GAAGRIA2GRIA4
SCHEMBL13611812 0.85 KDM4E (0.40) KDM4EALDH1A1HPGDL3MBTL1FNTA
SCHEMBL4381278 0.83 AR (0.39) KDM4EALDH1A1HPGDGAAKMT2A
SCHEMBL4373024 0.83 GRIA2 (0.52) KDM4EALDH1A1L3MBTL1TDP1GAA
SCHEMBL4373029 0.82 KDM4E (0.40) KDM4EALDH1A1HPGDL3MBTL1FNTA
SCHEMBL8288492 0.82 GRIA4 (0.47) KDM4EALDH1A1HPGDL3MBTL1FNTA
SCHEMBL4377035 0.81 FNTA (0.47) KDM4EALDH1A1HPGDGAAFNTA
SCHEMBL8289312 0.81 ALDH1A1 (0.45) KDM4EALDH1A1HPGDL3MBTL1TDP1
SCHEMBL13611763 0.80 GRIA4 (0.41) KDM4EALDH1A1HPGDL3MBTL1FNTA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7625932-B2 Pyrrole and pyrazole derivatives as potentiators of glutamate receptors ELI LILLY AND COMPANY (US) 2009-12-01 US disclosed
US-7625932-B2 Pyrrole and pyrazole derivatives as potentiators of glutamate receptors ELI LILLY AND COMPANY (US) 2009-12-01 US disclosed
EP-1670757-B1 PYRROLE AND PYRAZOLE DERIVATIVES AS POTENTIATORS OF GLUTAMATE RECEPTORS LILLY CO ELI (US) 2009-05-06 EP disclosed
EP-1670757-B1 PYRROLE AND PYRAZOLE DERIVATIVES AS POTENTIATORS OF GLUTAMATE RECEPTORS LILLY CO ELI (US) 2009-05-06 EP disclosed
US-20070066573-A1 Pyrrole and pyrazole derivatives as potentiators of glutamate receptors ELI LILLY AND COMPANY 2007-03-22 US disclosed
US-20070066573-A1 Pyrrole and pyrazole derivatives as potentiators of glutamate receptors ELI LILLY AND COMPANY 2007-03-22 US disclosed
WO-2005040110-A1 PYRROLE AND PYRAZOLE DERIVATIVES AS POTENTIATORS OF GLUTAMATE RECEPTORS ELI LILLY AND COMPANY (US) 2005-05-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070066573-A1 Pyrrole and pyrazole derivatives as potentiators of glutamate receptors GRIN1, GRIN3A, GRIK5 KDM4E 2620/4885ALDH1A1 2211/4885HPGD 1113/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.